MetaCap

Tyra Biosciences Inc. (TYRA)

NASDAQ: TYRAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

20.12+0.39 (+1.98%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

TYRA stock chart

Technical analysis

Key statistics

All statistics
EPS (TTM)
-$2.63
52-week range
18.25 – 40.65
Day range
19.62 – 20.44
Volume / Avg
467.58K / 852.56K
Beta
—

52-week range

$18.25$40.65

TYRA stock today

Shares of Tyra Biosciences (TYRA) finished higher on Nov 20 at $20.12, a gain of 1.98% or $0.39 per share, versus the S&P 500's 3.70% decline. At this level, TYRA sits near the bottom of its 52-week range of $18.25 to $40.65: 50.5% below the high, set on Apr 1, 2026 and 10.2% above the low. TYRA is down 23.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 4.7%.

Tyra Biosciences has posted a net loss over the last twelve months (EPS of -$2.63), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Tyra Biosciences

Company profile

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is FGFR3, which is in clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Todd Harris Ph.D.
Headquarters
Carlsbad, CA
Employees
87
IPO year
2021
Website
tyra.bio

Financial highlights

Full financials

Tyra Biosciences reported a net loss of $119.9 million, compared with a loss of $86.5 million a year earlier. Diluted earnings per share came in at -$2.01.

Tyra Biosciences annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-119.95M$-86.48M$-69.13M$-55.33M$-26.29M
EPS (diluted)$-2.01$-1.51$-1.62$-1.32$-1.91

Analyst forecast

Forecast

Consensus (15 analysts)

strong_buy

Avg. price target

$47.45+135.83%

  • Strong buy 2
  • Buy 12
  • Hold 1
  • Sell 0
  • Strong sell 0

Target range

Low $27.00High $59.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 10, 2026
EPS actual vs est.
$-0.74 vs $-0.66
Surprise
-12.12%

TYRA news

All TYRA news

Tyra Biosciences peers

Health Care sector
TYRA peer companies
CompanyPrice% ChgMarket capCompare
QUREuniQure N.V.19.35-4.35%$1.36Bvs TYRA
URGNUroGen Pharma Ltd.27.65-12.86%$1.36Bvs TYRA
RAPPRapport Therapeutics Inc.23.16-1.82%$1.37Bvs TYRA
PAHCPhibro Animal Health Corporation Class A33.29-2.32%$1.35Bvs TYRA
NBTXNanobiotix S.A. ADR26.50-2.98%$1.35Bvs TYRA
NUVBNuvation Bio Inc. Class A3.80-0.26%$1.34Bvs TYRA
ANABAnaptysBio Inc.46.63-1.62%$1.39Bvs TYRA
NRIXNurix Therapeutics Inc.12.85-5.55%$1.40Bvs TYRA

Indexes, lists and sector

Tyra Biosciences stock FAQ

What is Tyra Biosciences's stock price today?

TYRA last traded at $20.12 as of Nov 20, 4:00 PM EST, up 1.98% on the day. Prices are delayed at least 15 minutes.

Who is Tyra Biosciences's CEO?

Dr. Todd Harris Ph.D. is the chief executive officer of Tyra Biosciences Inc., which has about 87 employees.

What is the TYRA 52-week high?

The 52-week high for TYRA is $40.65 and the 52-week low is $18.25. The stock is currently 50.5% below its high.

Compare TYRA